- Home
- CLNN vs KALA Comparison
CLNN vs KALA Comparison
Compare CLNN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- KALA
- Stock Information
- Founded
- CLNN 2012
- KALA 2009
- Country
- CLNN United States
- KALA United States
- Employees
- CLNN N/A
- KALA N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- KALA Health Care
- Exchange
- CLNN Nasdaq
- KALA Nasdaq
- Market Cap
- CLNN 23.1M
- KALA 26.2M
- IPO Year
- CLNN N/A
- KALA 2017
- Fundamental
- Price
- CLNN $3.76
- KALA $5.26
- Analyst Decision
- CLNN Strong Buy
- KALA Strong Buy
- Analyst Count
- CLNN 5
- KALA 3
- Target Price
- CLNN $40.00
- KALA $14.00
- AVG Volume (30 Days)
- CLNN 141.3K
- KALA 64.7K
- Earning Date
- CLNN 08-06-2025
- KALA 08-05-2025
- Dividend Yield
- CLNN N/A
- KALA N/A
- EPS Growth
- CLNN N/A
- KALA N/A
- EPS
- CLNN N/A
- KALA N/A
- Revenue
- CLNN $350,000.00
- KALA N/A
- Revenue This Year
- CLNN N/A
- KALA N/A
- Revenue Next Year
- CLNN $1,753.57
- KALA N/A
- P/E Ratio
- CLNN N/A
- KALA N/A
- Revenue Growth
- CLNN N/A
- KALA N/A
- 52 Week Low
- CLNN $2.28
- KALA $2.92
- 52 Week High
- CLNN $7.59
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- CLNN 52.37
- KALA 68.75
- Support Level
- CLNN $4.12
- KALA $3.82
- Resistance Level
- CLNN $4.40
- KALA $4.41
- Average True Range (ATR)
- CLNN 0.26
- KALA 0.42
- MACD
- CLNN -0.06
- KALA 0.07
- Stochastic Oscillator
- CLNN 7.89
- KALA 92.00
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.